Healthcare and Medical Stocks List

This page shows information about the 50 largest healthcare and medical sector stocks including Eli Lilly and Company, Johnson & Johnson, AbbVie and UnitedHealth Group.

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$1,098.78 +0.21 (+0.02%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$1,101.49 +2.71 (+0.25%)
As of 06/18/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • The company has demonstrated impressive financial performance, with a return on equity exceeding 100%, indicating effective management and strong profitability.
  • Eli Lilly and Co's revenue has significantly increased, showcasing a year-over-year growth that reflects strong demand for its products.
  • Recent acquisitions, such as 4E Therapeutics, enhance its portfolio and expand its market presence, particularly in non-opioid pain treatments.

Cons of Eli Lilly and Company

  • Concerns regarding employer coverage and access could hinder the adoption of its top-selling obesity drugs, potentially impacting future revenue growth.
  • Increased competition in the obesity-drug market, particularly from companies like Novo Nordisk, may pressure market share and pricing strategies.
  • While the company has a strong pipeline, any delays or failures in drug development could negatively affect investor confidence and stock performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$1.03 trillion
P/E Ratio
39.03
Consensus Rating
Moderate Buy
Consensus Price Target
$1,227.74 (+11.7% Upside)
Volume
4.45 million shares
Average Volume
2.96 million shares
Today's Range
$1,088.66
$1,122.33
50-Day Range
$851.65
$1,161.75
52-Week Range
$623.78
$1,182.73
Dividend Yield
0.63%
Johnson & Johnson stock logo

2. Johnson & Johnson NYSE:JNJ

$228.37 -0.02 (-0.01%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$228.54 +0.17 (+0.08%)
As of 06/18/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • Johnson & Johnson has demonstrated strong financial performance, with a return on equity of 32.60%, indicating effective management and profitability relative to shareholder equity.
  • The company recently reported a quarterly revenue of $24.06 billion, surpassing analyst expectations, which reflects robust demand for its products and a solid market position.
  • Johnson & Johnson has increased its quarterly dividend to $1.34, showing a commitment to returning value to shareholders. This translates to an annualized dividend of $5.36, providing a yield of 2.3%.

Cons of Johnson & Johnson

  • Despite recent revenue growth, the EPS for the latest quarter was $2.70, which is lower than the $2.77 EPS reported in the same quarter last year, indicating potential challenges in maintaining earnings growth.
  • The company's payout ratio stands at 61.97%, which suggests that a significant portion of its earnings is being distributed as dividends. This could limit the funds available for reinvestment in growth opportunities.
  • Johnson & Johnson operates in a highly competitive healthcare market, which can lead to pressure on pricing and margins, potentially impacting future profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$549.78 billion
P/E Ratio
26.40
Consensus Rating
Moderate Buy
Consensus Price Target
$253.04 (+10.8% Upside)
Volume
18.99 million shares
Average Volume
7.51 million shares
Today's Range
$227.60
$232.75
50-Day Range
$221.17
$241.13
52-Week Range
$149.04
$251.71
Dividend Yield
2.35%
AbbVie stock logo

3. AbbVie NYSE:ABBV

$216.63 +0.14 (+0.06%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$216.88 +0.25 (+0.11%)
As of 06/18/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • The current stock price is around $212, which is significantly lower than its 1-year high, indicating potential for growth.
  • AbbVie recently reported a quarterly earnings per share (EPS) of $2.65, exceeding analyst expectations, which reflects strong financial performance.
  • The company has a diverse product portfolio and pipeline that spans multiple therapeutic areas, including immunology and oncology, which can drive future revenue growth.

Cons of AbbVie

  • AbbVie has a high price-to-earnings (P/E) ratio of 106.71, which may indicate that the stock is overvalued compared to its earnings.
  • The company has a negative return on equity of 576.45%, suggesting inefficiencies in generating profit from shareholders' equity.
  • AbbVie's dividend payout ratio is extremely high at 340.89%, which raises concerns about the sustainability of its dividend payments in the long term.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$382.49 billion
P/E Ratio
106.71
Consensus Rating
Moderate Buy
Consensus Price Target
$253.43 (+17.0% Upside)
Volume
9.59 million shares
Average Volume
5.00 million shares
Today's Range
$215.37
$222.35
50-Day Range
$197.24
$227.68
52-Week Range
$181.73
$244.81
Dividend Yield
3.20%
UnitedHealth Group stock logo

4. UnitedHealth Group NYSE:UNH

$400.86 -0.10 (-0.02%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$400.05 -0.81 (-0.20%)
As of 06/18/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. More about UnitedHealth Group

Pros of UnitedHealth Group

  • The company recently reported earnings per share (EPS) of $7.23, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
  • UnitedHealth Group has increased its quarterly dividend to $2.32 per share, reflecting a commitment to returning value to shareholders and suggesting financial stability.
  • The current stock price is around $720, which may present an attractive entry point for investors looking for exposure to the healthcare sector.

Cons of UnitedHealth Group

  • The company's net margin is relatively low at 2.68%, which may raise concerns about profitability compared to competitors in the healthcare sector.
  • UnitedHealth Group's dividend payout ratio is currently at 70.09%, indicating that a significant portion of earnings is being distributed as dividends, which could limit reinvestment in growth opportunities.
  • Analysts forecast an EPS of 18.32 for the current fiscal year, which is slightly above the company's own guidance, suggesting that meeting or exceeding expectations may be challenging.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$364.13 billion
P/E Ratio
30.28
Consensus Rating
Moderate Buy
Consensus Price Target
$409.75 (+2.2% Upside)
Volume
11.83 million shares
Average Volume
6.51 million shares
Today's Range
$399.15
$406.20
50-Day Range
$304.63
$412.57
52-Week Range
$234.60
$415.98
Dividend Yield
2.31%
Merck & Co., Inc. stock logo

5. Merck & Co., Inc. NYSE:MRK

$114.04 +0.17 (+0.15%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$114.07 +0.04 (+0.03%)
As of 06/18/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • The current stock price is around $119, reflecting a strong market position and investor confidence.
  • Merck has recently seen significant institutional investment, with firms like Panagora Asset Management increasing their holdings by over 410%, indicating strong belief in the company's future growth.
  • The company reported impressive quarterly earnings, exceeding revenue expectations, which suggests robust operational performance and potential for future profitability.

Cons of Merck & Co., Inc.

  • The company has a relatively high debt-to-equity ratio of 1.02, which may indicate financial risk if not managed properly.
  • Despite recent growth, the pharmaceutical sector faces regulatory challenges that could impact Merck's product pipeline and profitability.
  • Merck's price-to-earnings (P/E) ratio of 33.54 suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$281.24 billion
P/E Ratio
32.12
Consensus Rating
Moderate Buy
Consensus Price Target
$128.18 (+12.4% Upside)
Volume
29.52 million shares
Average Volume
11.17 million shares
Today's Range
$111.57
$114.94
50-Day Range
$109.33
$122.89
52-Week Range
$76.66
$125.14
Dividend Yield
2.99%
Novartis stock logo

6. Novartis NYSE:NVS

$147.17 +0.09 (+0.06%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$147.65 +0.48 (+0.32%)
As of 06/18/2026 07:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • The current stock price is around $121, which may present a favorable entry point for potential investors looking for growth in the pharmaceutical sector.
  • Novartis AG has a strong focus on innovative therapeutic areas, including oncology and immunology, which are critical for future growth and can lead to significant market opportunities.
  • The company has established collaborations with Alnylam Pharmaceuticals and Dawn Health, indicating a commitment to developing cutting-edge therapies and digital solutions, which can enhance its product portfolio.

Cons of Novartis

  • Despite recent growth, the short percentage of float is 0.21%, indicating some investor skepticism about the stock's future performance.
  • The company has a relatively high number of shares shorted, which can lead to increased volatility and potential downward pressure on the stock price.
  • With a days to cover ratio of 2.4, it may take time for short sellers to cover their positions, which could lead to short-term price fluctuations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$280.65 billion
P/E Ratio
21.08
Consensus Rating
Hold
Consensus Price Target
$141.20 (-4.1% Downside)
Volume
1.87 million shares
Average Volume
1.65 million shares
Today's Range
$146.92
$150.08
50-Day Range
$142.99
$155.11
52-Week Range
$112.34
$170.46
Dividend Yield
2.09%
Novo Nordisk A/S stock logo

7. Novo Nordisk A/S NYSE:NVO

$43.20 +0.01 (+0.02%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$43.09 -0.11 (-0.25%)
As of 06/18/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • Recent analyst upgrades, including an "outperform" rating with a target price significantly higher than the current stock price, indicate strong future potential.
  • The current stock price is around $41, which may present a buying opportunity for investors looking for value in a leading pharmaceutical company.
  • Strong financial performance with a reported earnings per share of $1.03 and a high return on equity of over 63%, suggesting effective management and profitability.

Cons of Novo Nordisk A/S

  • Recent downgrades from some analysts, including a reduction in target prices, may indicate concerns about future growth prospects.
  • The stock has experienced volatility, with a 52-week high of $81.44 and a low of $35.12, suggesting potential risks for investors.
  • High competition in the pharmaceutical sector, particularly in diabetes care, could impact Novo Nordisk's market share and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$192.84 billion
P/E Ratio
10.14
Consensus Rating
Hold
Consensus Price Target
$65.56 (+51.8% Upside)
Volume
8.99 million shares
Average Volume
11.54 million shares
Today's Range
$42.52
$44.00
50-Day Range
$37.42
$47.13
52-Week Range
$35.12
$74.38
Dividend Yield
4.05%
Amgen stock logo

8. Amgen NASDAQ:AMGN

$337.60 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$336.12 -1.48 (-0.44%)
As of 06/18/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • Amgen Inc. has a strong projected earnings per share (EPS) of 22.38 for the current year, indicating solid profitability potential.
  • The current stock price is around $323, which may present a buying opportunity for investors looking for value in the biotechnology sector.
  • Recent analyst ratings show a consensus target price of approximately $354.42, suggesting potential upside from the current price.

Cons of Amgen

  • Recent insider transactions, such as the sale of shares by a senior vice president, may raise concerns about the company's short-term outlook.
  • Analyst ratings include a mix of "Hold" and "Sell" recommendations, indicating some uncertainty about the stock's performance.
  • Price targets from analysts have shown some downward adjustments, which could signal potential challenges ahead for the company.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$182.21 billion
P/E Ratio
23.49
Consensus Rating
Hold
Consensus Price Target
$354.42 (+5.0% Upside)
Volume
8.12 million shares
Average Volume
2.85 million shares
Today's Range
$334.05
$345.00
50-Day Range
$324.39
$355.60
52-Week Range
$267.83
$391.29
Dividend Yield
2.99%
Thermo Fisher Scientific stock logo

9. Thermo Fisher Scientific NYSE:TMO

$465.98 +1.37 (+0.30%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$462.03 -3.95 (-0.85%)
As of 06/18/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • The current stock price is around $620, reflecting strong market interest and potential for growth.
  • Thermo Fisher Scientific Inc. has a low dividend payout ratio of 10.34%, indicating that the company retains a significant portion of its earnings for reinvestment, which can lead to future growth.
  • Analysts have given the stock a consensus target price of approximately $608.95, suggesting that there is room for price appreciation based on current valuations.

Cons of Thermo Fisher Scientific

  • Recent downgrades from analysts, including a reduction in price targets, may indicate concerns about the company's short-term performance.
  • The dividend yield is relatively low at 0.4%, which may not attract income-focused investors looking for higher returns from dividends.
  • Insider selling, such as the COO's recent sale of shares, could signal a lack of confidence in the company's near-term prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$172.66 billion
P/E Ratio
25.62
Consensus Rating
Moderate Buy
Consensus Price Target
$608.95 (+30.7% Upside)
Volume
3.31 million shares
Average Volume
2.20 million shares
Today's Range
$459.00
$467.94
50-Day Range
$438.16
$531.69
52-Week Range
$390.50
$643.99
Dividend Yield
0.40%
Abbott Laboratories stock logo

10. Abbott Laboratories NYSE:ABT

$88.48 +0.07 (+0.08%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$88.32 -0.17 (-0.19%)
As of 06/18/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • The current stock price is around $130, reflecting a strong market position and investor confidence in Abbott Laboratories' growth potential.
  • Abbott Laboratories has a diverse portfolio that includes advanced diagnostics and medical devices, which are critical in the healthcare sector, especially in response to ongoing health challenges.
  • The company has received multiple "Buy" ratings from analysts, indicating positive sentiment and potential for stock appreciation.

Cons of Abbott Laboratories

  • Recent price target reductions by major analysts, such as Royal Bank of Canada and Wells Fargo, may indicate concerns about future growth and profitability.
  • Despite a strong product lineup, Abbott Laboratories faces intense competition in the healthcare market, which could impact market share and pricing power.
  • The company's reliance on a few key product lines for revenue could pose risks if those products face regulatory challenges or market saturation.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$153.99 billion
P/E Ratio
24.78
Consensus Rating
Moderate Buy
Consensus Price Target
$118.30 (+33.7% Upside)
Volume
41.95 million shares
Average Volume
12.83 million shares
Today's Range
$87.76
$89.44
50-Day Range
$82.58
$102.73
52-Week Range
$81.97
$139.06
Dividend Yield
2.85%
Gilead Sciences stock logo

11. Gilead Sciences NASDAQ:GILD

$123.76 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$123.74 -0.02 (-0.01%)
As of 06/18/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More about Gilead Sciences

Pros of Gilead Sciences

  • The company has a strong focus on areas of high unmet medical need, particularly in antiviral therapies, oncology, and inflammatory diseases, which positions it well for future growth.
  • Recent advancements in clinical trials, such as the Denikitug trial for tough-to-treat colorectal cancer, highlight Gilead's commitment to innovation and expanding its product pipeline.
  • Insider trading activity indicates confidence in the company, with executives recently selling shares under a pre-arranged trading plan, suggesting they believe in the company's future performance.

Cons of Gilead Sciences

  • Recent commentary suggests that Gilead’s stock has experienced technical pressure, pulling back from its 50-day and 200-day moving averages, which may indicate a bearish trend.
  • Analysts have slightly lowered earnings estimates for FY2026, reflecting cautious sentiment about the company's near-term financial performance.
  • Insider sales, while sometimes viewed positively, can also raise concerns about the executives' confidence in the company's short-term outlook.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$153.66 billion
P/E Ratio
16.86
Consensus Rating
Moderate Buy
Consensus Price Target
$158.41 (+28.0% Upside)
Volume
14.25 million shares
Average Volume
8.24 million shares
Today's Range
$122.43
$126.39
50-Day Range
$121.48
$142.09
52-Week Range
$104.46
$157.29
Dividend Yield
2.65%
Intuitive Surgical stock logo

12. Intuitive Surgical NASDAQ:ISRG

$406.78 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$408.13 +1.35 (+0.33%)
As of 06/18/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • The current stock price is around $424, reflecting the company's strong market position in robotic-assisted surgical systems.
  • Intuitive Surgical, Inc. is a leader in the medical technology sector, particularly known for its da Vinci surgical systems, which enhance precision in minimally invasive surgeries.
  • Recent insider trading activity indicates confidence in the company's future, with executives executing trades under a pre-arranged plan, suggesting strategic financial management.

Cons of Intuitive Surgical

  • Insider sales have occurred recently, with executives selling shares, which may raise concerns about their confidence in the company's short-term performance.
  • Only 0.60% of the stock is owned by company insiders, indicating a potential lack of alignment between management and shareholder interests.
  • The company has experienced a significant decrease in insider ownership, which could signal potential challenges in maintaining investor confidence.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$144.07 billion
P/E Ratio
49.31
Consensus Rating
Moderate Buy
Consensus Price Target
$573.42 (+41.0% Upside)
Volume
4.40 million shares
Average Volume
2.33 million shares
Today's Range
$400.93
$409.64
50-Day Range
$402.18
$483.62
52-Week Range
$396.68
$603.88
Dividend Yield
N/A
Pfizer stock logo

13. Pfizer NYSE:PFE

$25.26 +0.05 (+0.18%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$25.25 0.00 (-0.02%)
As of 06/18/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • The current stock price is around $28, which is near its twelve-month high, indicating strong market performance.
  • Pfizer Inc. reported earnings per share (EPS) of $0.75 for the latest quarter, surpassing analysts' expectations, which reflects robust financial health.
  • The company has shown a year-over-year revenue increase of 5.4%, suggesting growth and resilience in its business operations.

Cons of Pfizer

  • The dividend payout ratio is 131.30%, which suggests that the company is paying out more in dividends than it earns, raising concerns about sustainability.
  • Pfizer Inc. experienced a decline in EPS from $0.92 in the same quarter last year, indicating potential challenges in maintaining profitability.
  • Analysts have mixed ratings on the stock, with a consensus rating of "Hold," which may signal uncertainty about future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$143.68 billion
P/E Ratio
19.28
Consensus Rating
Hold
Consensus Price Target
$28.82 (+14.1% Upside)
Volume
119.42 million shares
Average Volume
35.64 million shares
Today's Range
$24.94
$25.66
50-Day Range
$25.26
$27.58
52-Week Range
$23.11
$28.75
Dividend Yield
6.82%
CVS Health stock logo

14. CVS Health NYSE:CVS

$98.26 -0.06 (-0.06%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$99.06 +0.79 (+0.81%)
As of 06/18/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • The current stock price is around $87, which may present a buying opportunity for investors looking for value in the healthcare sector.
  • CVS Health Co. reported strong earnings recently, with earnings per share (EPS) of $2.57, exceeding analyst expectations, indicating robust financial performance.
  • The company has shown a year-over-year revenue increase of 6.2%, suggesting growth potential and resilience in its business model.

Cons of CVS Health

  • The company's debt-to-equity ratio stands at 0.78, indicating a significant level of debt which could pose risks in a rising interest rate environment.
  • CVS Health Co. has a high payout ratio of 117.18%, suggesting that it is returning more to shareholders than it is earning, which could be unsustainable in the long run.
  • Despite recent growth, the net margin of 0.72% is relatively low, indicating that the company may face challenges in maintaining profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$125.45 billion
P/E Ratio
43.29
Consensus Rating
Moderate Buy
Consensus Price Target
$100.68 (+2.5% Upside)
Volume
21.55 million shares
Average Volume
7.73 million shares
Today's Range
$97.84
$99.22
50-Day Range
$75.19
$101.87
52-Week Range
$58.50
$102.77
Dividend Yield
2.71%
Danaher stock logo

15. Danaher NYSE:DHR

$177.74 +0.57 (+0.32%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$177.53 -0.21 (-0.12%)
As of 06/18/2026 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • The company has demonstrated strong financial performance, with a recent earnings per share (EPS) of $2.06, exceeding analyst expectations, indicating robust profitability.
  • Danaher Co. has a solid current ratio of 1.87, suggesting that it has sufficient short-term assets to cover its short-term liabilities, which is a positive indicator of financial health.
  • With a debt-to-equity ratio of 0.33, Danaher Co. maintains a conservative approach to leverage, reducing financial risk and enhancing stability for investors.

Cons of Danaher

  • The company’s recent revenue of $5.95 billion fell short of analyst estimates of $6 billion, indicating potential challenges in meeting growth expectations.
  • Despite a positive EPS, the net margin of 14.89% may suggest that profit margins are under pressure, which could affect future profitability.
  • Some analysts have lowered their price targets for Danaher Co., reflecting a cautious outlook on the stock's near-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$125.40 billion
P/E Ratio
34.38
Consensus Rating
Moderate Buy
Consensus Price Target
$233.61 (+31.4% Upside)
Volume
6.26 million shares
Average Volume
3.77 million shares
Today's Range
$174.22
$178.51
50-Day Range
$161.95
$198.58
52-Week Range
$160.93
$242.80
Dividend Yield
0.90%
Stryker stock logo

16. Stryker NYSE:SYK

$308.62 +0.82 (+0.26%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$307.50 -1.11 (-0.36%)
As of 06/18/2026 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • The company has shown a consistent revenue growth of 2.6% year-over-year, indicating a stable demand for its medical technology products.
  • Stryker Co. has set an ambitious FY 2026 guidance with an expected EPS between 14.900 and 15.100, suggesting strong future profitability.
  • The current stock price is around $306, which may present a buying opportunity for investors looking for growth in the medical technology sector.

Cons of Stryker

  • Insider selling has been significant, with executives selling over 323,000 shares recently, which may raise concerns about the company's future performance.
  • The dividend payout ratio is currently at 40.74%, which, while sustainable, could limit the company's ability to reinvest in growth opportunities.
  • Some analysts have downgraded their ratings, indicating mixed sentiments about the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$118.00 billion
P/E Ratio
35.72
Consensus Rating
Moderate Buy
Consensus Price Target
$395.33 (+28.1% Upside)
Volume
3.43 million shares
Average Volume
2.48 million shares
Today's Range
$299.36
$311.54
50-Day Range
$282.85
$347.28
52-Week Range
$281.00
$404.87
Dividend Yield
1.14%
Vertex Pharmaceuticals stock logo

17. Vertex Pharmaceuticals NASDAQ:VRTX

$451.63 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$452.75 +1.12 (+0.25%)
As of 06/18/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • The current stock price is around $437, which reflects a strong performance in the biotechnology sector.
  • Vertex Pharmaceuticals Incorporated reported a significant earnings per share of $4.47, surpassing analysts' expectations, indicating robust financial health.
  • The company has demonstrated a year-over-year revenue growth of 8.3%, showcasing its ability to expand and succeed in the competitive market.

Cons of Vertex Pharmaceuticals

  • The P/E ratio of 26.39 may suggest that the stock is overvalued compared to its earnings, which could deter value-focused investors.
  • With a beta of 0.30, the stock is less volatile than the market, which may not appeal to investors seeking high-risk, high-reward opportunities.
  • Despite recent successes, the biotechnology sector is highly competitive and subject to rapid changes, which can pose risks to future growth.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$114.63 billion
P/E Ratio
26.79
Consensus Rating
Moderate Buy
Consensus Price Target
$555.91 (+23.1% Upside)
Volume
2.99 million shares
Average Volume
1.24 million shares
Today's Range
$450.39
$464.98
50-Day Range
$423.24
$458.99
52-Week Range
$362.50
$507.92
Dividend Yield
N/A
Bristol Myers Squibb stock logo

18. Bristol Myers Squibb NYSE:BMY

$54.10 +0.10 (+0.19%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$54.07 -0.03 (-0.05%)
As of 06/18/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol Myers Squibb

Pros of Bristol Myers Squibb

  • The current stock price is around $61, which is close to the consensus price target, indicating potential for growth.
  • The company reported strong quarterly earnings, exceeding analysts' expectations with earnings per share of $1.58, showcasing its profitability.
  • Bristol-Myers Squibb has a solid revenue stream, with quarterly revenue of $11.49 billion, reflecting a year-over-year increase of 2.6%.

Cons of Bristol Myers Squibb

  • The company experienced a decline in earnings per share compared to the same quarter last year, which was $1.80, raising concerns about profitability trends.
  • The payout ratio is currently at 70.79%, which may indicate that a significant portion of earnings is being distributed as dividends, potentially limiting reinvestment in growth.
  • Market analysts have mixed ratings, with some firms downgrading their outlook, which could signal uncertainty about the company's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$110.27 billion
P/E Ratio
15.20
Consensus Rating
Hold
Consensus Price Target
$61.31 (+13.3% Upside)
Volume
30.95 million shares
Average Volume
12.03 million shares
Today's Range
$53.44
$55.33
50-Day Range
$54.10
$60.75
52-Week Range
$42.52
$62.89
Dividend Yield
4.67%
Sanofi stock logo

19. Sanofi NASDAQ:SNY

$42.38 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$42.28 -0.10 (-0.24%)
As of 06/18/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • The current stock price is around $43.60, which is near its 1-year low, potentially offering a buying opportunity for value investors.
  • Sanofi has a strong market capitalization of approximately $108.66 billion, indicating a solid position in the pharmaceutical industry.
  • The company maintains a low debt-to-equity ratio of 0.20, suggesting financial stability and lower risk associated with debt obligations.

Cons of Sanofi

  • Despite a solid market cap, the stock has shown volatility, with a 1-year high of $60.12 and a low of $44.00, indicating potential risks in price fluctuations.
  • The average target price from analysts is $62.67, which may suggest limited upside potential compared to the current stock price.
  • Sanofi's quick ratio of 0.73 indicates that the company may face challenges in meeting short-term liabilities, which could be a concern for liquidity.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$102.75 billion
P/E Ratio
11.84
Consensus Rating
Hold
Consensus Price Target
$51.00 (+20.3% Upside)
Volume
4.09 million shares
Average Volume
2.54 million shares
Today's Range
$41.86
$42.47
50-Day Range
$42.37
$48.06
52-Week Range
$41.85
$52.68
Dividend Yield
4.16%
GSK stock logo

20. GSK NYSE:GSK

$50.76 +0.09 (+0.18%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$50.71 -0.05 (-0.10%)
As of 06/18/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • The current stock price is around $43.16, which may present a favorable entry point for potential investors looking for value.
  • GSK plc has shown a positive fifty-two week performance, indicating a potential upward trend in its stock value.
  • Institutional ownership is relatively high, suggesting confidence from large investors in GSK plc's future prospects.

Cons of GSK

  • There has been a decline in the short percentage of float, which could suggest that some investors are losing confidence in the stock's potential for growth.
  • The recent fifty-two week performance has also shown a decline, indicating potential challenges in the company's market position.
  • Average daily volume has decreased, which may suggest reduced investor interest and liquidity in GSK plc's stock.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$102.61 billion
P/E Ratio
13.19
Consensus Rating
Hold
Consensus Price Target
$53.00 (+4.4% Upside)
Volume
4.22 million shares
Average Volume
3.59 million shares
Today's Range
$50.43
$51.94
50-Day Range
$49.06
$59.19
52-Week Range
$35.45
$61.69
Dividend Yield
3.58%
Medtronic stock logo

21. Medtronic NYSE:MDT

$79.37 +0.03 (+0.03%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$79.40 +0.03 (+0.04%)
As of 06/18/2026 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • The company recently reported earnings per share (EPS) of $1.55, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
  • Medtronic plc's revenue for the quarter reached approximately $9.81 billion, surpassing forecasts, suggesting robust demand for its medical technology products.
  • The firm has increased its quarterly dividend to $0.72 per share, reflecting a commitment to returning value to shareholders, with an annualized yield of about 3.6%.

Cons of Medtronic

  • The net margin of 13.20% indicates that while the company is profitable, there may be concerns about cost management and competitive pressures in the medical technology sector.
  • Medtronic plc's EPS has decreased from $1.62 in the same quarter last year, which could signal potential challenges in maintaining growth and profitability.
  • With a payout ratio of 76.14%, a significant portion of earnings is being distributed as dividends, which may limit the company's ability to reinvest in growth opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$101.86 billion
P/E Ratio
21.28
Consensus Rating
Moderate Buy
Consensus Price Target
$99.00 (+24.7% Upside)
Volume
21.57 million shares
Average Volume
11.46 million shares
Today's Range
$78.45
$79.51
50-Day Range
$73.72
$88.11
52-Week Range
$73.31
$106.33
Dividend Yield
3.58%
McKesson stock logo

22. McKesson NYSE:MCK

$750.23 -0.40 (-0.05%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$762.50 +12.27 (+1.64%)
As of 06/18/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • The company recently reported earnings per share (EPS) of $11.69, exceeding analyst expectations, which indicates strong financial performance and potential for growth.
  • McKesson Co. has shown a year-over-year revenue increase of 6.0%, suggesting a positive trend in its business operations and market demand.
  • The current stock price is around $720, reflecting a stable valuation in the healthcare sector, which can be attractive for long-term investors.

Cons of McKesson

  • McKesson Co. has a negative return on equity of 345.35%, which may raise concerns about its efficiency in generating profits from shareholders' equity.
  • The company’s revenue for the latest quarter fell short of analyst estimates, which could indicate challenges in meeting market expectations.
  • With a net margin of only 1.18%, McKesson Co. may face difficulties in maintaining profitability, especially in a competitive healthcare market.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$87.88 billion
P/E Ratio
19.50
Consensus Rating
Moderate Buy
Consensus Price Target
$960.53 (+28.0% Upside)
Volume
2.48 million shares
Average Volume
999,764 shares
Today's Range
$747.40
$778.01
50-Day Range
$724.87
$873.15
52-Week Range
$637.00
$999.00
Dividend Yield
0.44%
Elevance Health stock logo

23. Elevance Health NYSE:ELV

$388.77 +0.27 (+0.07%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$384.89 -3.88 (-1.00%)
As of 06/18/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$84.37 billion
P/E Ratio
16.54
Consensus Rating
Moderate Buy
Consensus Price Target
$416.11 (+7.0% Upside)
Volume
3.53 million shares
Average Volume
1.62 million shares
Today's Range
$387.08
$393.91
50-Day Range
$311.41
$424.16
52-Week Range
$273.71
$426.98
Dividend Yield
1.77%
HCA Healthcare stock logo

24. HCA Healthcare NYSE:HCA

$375.37 +0.20 (+0.05%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$376.20 +0.82 (+0.22%)
As of 06/18/2026 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • The current stock price is around $439, which is significantly lower than its one-year high, indicating potential for price appreciation.
  • HCA Healthcare, Inc. reported a year-over-year revenue increase of 4.3%, showcasing its ability to grow even in challenging market conditions.
  • The company has a solid market capitalization of approximately $82.59 billion, reflecting its strong position in the healthcare sector.

Cons of HCA Healthcare

  • The company has a negative return on equity of 295.93%, indicating potential inefficiencies in generating profit from shareholders' equity.
  • HCA Healthcare, Inc. missed its earnings per share estimate in the latest quarter, which may raise concerns about its short-term performance.
  • The beta of 1.12 suggests that the stock is more volatile than the market, which could lead to higher risk for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$83.23 billion
P/E Ratio
12.91
Consensus Rating
Moderate Buy
Consensus Price Target
$506.14 (+34.8% Upside)
Volume
2.63 million shares
Average Volume
1.64 million shares
Today's Range
$374.31
$391.85
50-Day Range
$360.99
$507.17
52-Week Range
$330.00
$556.52
Dividend Yield
0.83%
Cigna Group stock logo

25. Cigna Group NYSE:CI

$279.63 +0.36 (+0.13%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$283.54 +3.91 (+1.40%)
As of 06/18/2026 07:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about Cigna Group

Pros of Cigna Group

  • The Cigna Group recently reported strong earnings, exceeding expectations with earnings per share significantly above consensus estimates, indicating robust financial health.
  • The company has a solid return on equity, showcasing effective management and profitability, which can be attractive to investors looking for stable returns.
  • The current stock price is around $340, reflecting positive market sentiment and potential for growth, making it an appealing option for investors.

Cons of Cigna Group

  • Despite recent earnings growth, the company's net margin is relatively low, which may indicate challenges in cost management and profitability compared to peers.
  • Some analysts have downgraded their ratings, reflecting concerns about market conditions and potential volatility in the healthcare sector.
  • The dividend payout ratio is at 26.45%, which, while sustainable, may limit the company's ability to reinvest in growth opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$73.88 billion
P/E Ratio
11.85
Consensus Rating
Moderate Buy
Consensus Price Target
$338.30 (+21.0% Upside)
Volume
2.44 million shares
Average Volume
1.43 million shares
Today's Range
$279.20
$286.19
50-Day Range
$269.01
$300.36
52-Week Range
$239.51
$338.89
Dividend Yield
2.23%
Boston Scientific stock logo

26. Boston Scientific NYSE:BSX

$45.30 +0.01 (+0.03%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$45.43 +0.13 (+0.28%)
As of 06/18/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • The company has demonstrated strong financial performance, with quarterly revenue increasing significantly on a year-over-year basis, indicating robust demand for its products.
  • Boston Scientific Co. has set ambitious earnings per share (EPS) guidance for Q2 2026 and FY 2026, suggesting confidence in future profitability and growth.
  • Insider buying activity has been notable, with directors purchasing shares at prices around $56, which may indicate that they believe the stock is undervalued and a good investment opportunity.

Cons of Boston Scientific

  • Despite the positive revenue growth, the overall market conditions can be unpredictable, which may impact the company's performance and stock price.
  • Insider ownership remains relatively low at 0.34%, which could suggest a lack of alignment between management and shareholders' interests.
  • The stock repurchase plan, while a positive signal, may also indicate that the company lacks better investment opportunities for its capital, raising concerns about future growth potential.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$67.32 billion
P/E Ratio
18.95
Consensus Rating
Moderate Buy
Consensus Price Target
$85.08 (+87.8% Upside)
Volume
30.84 million shares
Average Volume
21.99 million shares
Today's Range
$44.44
$45.48
50-Day Range
$44.86
$65.89
52-Week Range
$44.44
$109.50
Dividend Yield
N/A
Regeneron Pharmaceuticals stock logo

27. Regeneron Pharmaceuticals NASDAQ:REGN

$609.94 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$607.02 -2.92 (-0.48%)
As of 06/18/2026 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • The current stock price is around $720, which reflects a strong performance in the biotechnology sector.
  • Regeneron Pharmaceuticals, Inc. reported a significant year-over-year revenue increase of 19.0%, indicating robust growth and demand for its products.
  • The company has a low debt-to-equity ratio, suggesting a strong balance sheet and financial stability, which can be attractive to investors looking for lower risk.

Cons of Regeneron Pharmaceuticals

  • The stock has a relatively low beta of 0.25, which indicates lower volatility but may also suggest limited growth potential compared to more aggressive investments.
  • Despite its strong performance, the company has a modest dividend yield of 0.6%, which may not be appealing for income-focused investors.
  • Regeneron Pharmaceuticals, Inc. has a payout ratio of 9.16%, indicating that a small portion of earnings is returned to shareholders, which may limit future dividend growth.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$64.48 billion
P/E Ratio
14.86
Consensus Rating
Moderate Buy
Consensus Price Target
$792.65 (+30.0% Upside)
Volume
2.54 million shares
Average Volume
1.10 million shares
Today's Range
$598.19
$616.24
50-Day Range
$600.66
$767.85
52-Week Range
$506.38
$821.11
Dividend Yield
0.62%
argenex stock logo

28. argenex NASDAQ:ARGX

$877.72 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$878.14 +0.41 (+0.05%)
As of 06/18/2026 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenex

Pros of argenex

  • The current stock price is around $799, indicating a strong market position and potential for growth.
  • Recent short interest data shows a relatively low short percentage of float, suggesting that investors are not heavily betting against the stock.
  • With an average daily volume of approximately 346,000 shares, there is good liquidity, allowing for easier entry and exit from positions.

Cons of argenex

  • Despite the current stock price, the company has not demonstrated significant price appreciation over the past year, which may raise concerns about its growth prospects.
  • The outstanding shares are high, which could dilute earnings per share if the company issues more shares in the future.
  • There is no institutional ownership, which may indicate a lack of confidence from larger investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$54.58 billion
P/E Ratio
39.08
Consensus Rating
Moderate Buy
Consensus Price Target
$1,019.50 (+16.2% Upside)
Volume
351,970 shares
Average Volume
296,186 shares
Today's Range
$863.96
$902.89
50-Day Range
$775.03
$898.94
52-Week Range
$510.05
$934.62
Dividend Yield
N/A
Cencora stock logo

29. Cencora NYSE:COR

$271.99 +0.16 (+0.06%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$275.42 +3.43 (+1.26%)
As of 06/18/2026 06:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • The current stock price is around $265, which may present a buying opportunity for investors looking for value.
  • Cencora, Inc. has a strong market capitalization of approximately $51.58 billion, indicating a solid position in the healthcare services sector.
  • The company has received multiple "overweight" ratings from analysts, suggesting confidence in its growth potential.

Cons of Cencora

  • The company recently missed earnings per share estimates, which could raise concerns about its short-term performance.
  • There is a relatively high debt-to-equity ratio of 3.40, indicating that the company relies significantly on debt financing, which can be risky.
  • Despite a positive revenue trend, the net margin is only 0.78%, suggesting that profitability may be a concern.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$52.89 billion
P/E Ratio
20.86
Consensus Rating
Moderate Buy
Consensus Price Target
$374.00 (+37.5% Upside)
Volume
3.40 million shares
Average Volume
1.39 million shares
Today's Range
$270.03
$278.84
50-Day Range
$253.20
$327.52
52-Week Range
$244.82
$377.54
Dividend Yield
0.88%
Cardinal Health stock logo

30. Cardinal Health NYSE:CAH

$222.08 +0.31 (+0.14%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$221.54 -0.54 (-0.24%)
As of 06/18/2026 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • Cardinal Health, Inc. has set its FY 2026 guidance at an earnings per share (EPS) range of 10.700-10.80, indicating strong financial performance expectations.
  • The company recently increased its quarterly dividend to $0.5158 per share, reflecting a commitment to returning value to shareholders and a healthy dividend payout ratio of 31.19%.
  • Research analysts forecast an EPS of 10.76 for the current fiscal year, suggesting that the company is on track to meet or exceed its financial targets.

Cons of Cardinal Health

  • Despite the positive outlook, some analysts have lowered their price targets for Cardinal Health, Inc., which may indicate concerns about future performance.
  • The company operates in a highly competitive healthcare sector, which can impact market share and profitability.
  • There is a risk associated with the company's reliance on the distribution of pharmaceuticals and medical products, which can be affected by regulatory changes and supply chain disruptions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$51.94 billion
P/E Ratio
33.96
Consensus Rating
Moderate Buy
Consensus Price Target
$246.93 (+11.2% Upside)
Volume
4.18 million shares
Average Volume
2.14 million shares
Today's Range
$219.47
$226.17
50-Day Range
$182.62
$227.63
52-Week Range
$137.75
$233.60
Dividend Yield
0.92%
Edwards Lifesciences stock logo

31. Edwards Lifesciences NYSE:EW

$87.51 +0.15 (+0.17%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$86.97 -0.53 (-0.61%)
As of 06/18/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More about Edwards Lifesciences

Pros of Edwards Lifesciences

  • The company recently reported earnings per share of $0.78, exceeding expectations, which indicates strong financial performance and potential for growth.
  • With a market capitalization of approximately $49.37 billion, Edwards Lifesciences Co. is a significant player in the medical technology sector, suggesting stability and potential for long-term investment.
  • The current stock price is around $83, which is within a reasonable range compared to its one-year high of $89.48, indicating potential for appreciation.

Cons of Edwards Lifesciences

  • The P/E ratio of 45.61 indicates that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • Insider selling activity has been noted, with significant shares sold recently, which may raise concerns about the company's future prospects from a management perspective.
  • The stock has a beta of 0.87, suggesting it is less volatile than the market, which may not appeal to investors seeking high-risk, high-reward opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$50.30 billion
P/E Ratio
46.55
Consensus Rating
Moderate Buy
Consensus Price Target
$95.96 (+9.7% Upside)
Volume
5.54 million shares
Average Volume
4.82 million shares
Today's Range
$86.52
$87.83
50-Day Range
$77.11
$88.56
52-Week Range
$72.30
$89.60
Dividend Yield
N/A
Takeda Pharmaceutical stock logo

32. Takeda Pharmaceutical NYSE:TAK

$15.64 +0.01 (+0.03%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$15.62 -0.02 (-0.13%)
As of 06/18/2026 05:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • The current stock price is around $13.73, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • Takeda Pharmaceutical Company Limited has a diverse portfolio of products across various therapeutic areas, including oncology and immunology, which can help mitigate risks associated with reliance on a single product line.
  • The company has established numerous collaborations and licensing agreements with leading biotech firms, enhancing its research capabilities and potential for innovative drug development.

Cons of Takeda Pharmaceutical

  • The institutional ownership percentage is relatively low, which may indicate a lack of confidence from larger investors in the company's future prospects.
  • Despite recent positive trends, the overall market for pharmaceutical products can be volatile, influenced by regulatory changes and competitive pressures.
  • The company has a high number of shares shorted, which could indicate that some investors are betting against the stock, reflecting potential concerns about its performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$49.74 billion
P/E Ratio
40.09
Consensus Rating
Moderate Buy
Consensus Price Target
N/A
Volume
2.44 million shares
Average Volume
2.71 million shares
Today's Range
$15.52
$15.77
50-Day Range
$15.02
$18.47
52-Week Range
$12.99
$18.90
Dividend Yield
1.61%
IDEXX Laboratories stock logo

33. IDEXX Laboratories NASDAQ:IDXX

$562.09 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$559.66 -2.43 (-0.43%)
As of 06/18/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • The company reported strong earnings per share of $3.47 for the latest quarter, exceeding expectations, which indicates robust financial health and effective management.
  • IDEXX Laboratories, Inc. has demonstrated impressive revenue growth, with a year-over-year increase of 14.3%, suggesting a strong demand for its diagnostic products and services.
  • The current stock price is around $720, reflecting investor confidence and a solid market position in the diagnostic products sector.

Cons of IDEXX Laboratories

  • Despite recent growth, the competitive landscape in the diagnostic market is intensifying, which could pressure margins and market share.
  • The net margin of 24.63%, while healthy, may face challenges if operational costs rise or if pricing pressures emerge from competitors.
  • Market analysts have forecasted earnings per share of 14.68 for the current fiscal year, which, if not met, could lead to negative investor sentiment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$44.34 billion
P/E Ratio
41.39
Consensus Rating
Moderate Buy
Consensus Price Target
$751.00 (+33.6% Upside)
Volume
1.23 million shares
Average Volume
589,374 shares
Today's Range
$546.18
$563.85
50-Day Range
$528.68
$589.25
52-Week Range
$506.91
$769.98
Dividend Yield
N/A
Humana stock logo

34. Humana NYSE:HUM

$360.84 +0.19 (+0.05%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$360.00 -0.84 (-0.23%)
As of 06/18/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • The current stock price is around $263.86, which is significantly lower than its 52-week high, indicating potential for growth.
  • Humana Inc. reported strong earnings recently, with earnings per share (EPS) surpassing analyst expectations, showcasing robust financial performance.
  • The company has a solid market capitalization of $44.34 billion, reflecting its stability and presence in the health insurance sector.

Cons of Humana

  • The P/E ratio of 39.50 suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • Recent analyst ratings show mixed sentiments, with several firms downgrading their ratings, indicating uncertainty about future performance.
  • The company experienced a decline in EPS compared to the same quarter last year, which may raise concerns about its growth trajectory.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$43.30 billion
P/E Ratio
38.59
Consensus Rating
Hold
Consensus Price Target
$291.35 (-19.3% Downside)
Volume
3.57 million shares
Average Volume
1.26 million shares
Today's Range
$357.42
$369.89
50-Day Range
$192.01
$380.27
52-Week Range
$163.11
$380.86
Dividend Yield
0.98%
Becton, Dickinson and Company stock logo

35. Becton, Dickinson and Company NYSE:BDX

$143.99 +0.01 (+0.00%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$143.01 -0.97 (-0.68%)
As of 06/18/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • The company has a strong dividend yield of 2.8%, providing a steady income stream for investors.
  • Recent earnings reports show that Becton, Dickinson and Company has exceeded consensus estimates, indicating strong financial performance.
  • Analysts have a generally positive outlook, with several recent upgrades to price targets, suggesting potential for stock appreciation.

Cons of Becton, Dickinson and Company

  • The company has a high dividend payout ratio of 106.33%, which may raise concerns about sustainability in future payouts.
  • Recent insider selling by executives could signal a lack of confidence in the company's short-term performance.
  • Market volatility and economic uncertainties could impact the stock's performance, especially in the healthcare sector.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$39.67 billion
P/E Ratio
36.45
Consensus Rating
Hold
Consensus Price Target
$181.00 (+25.7% Upside)
Volume
6.23 million shares
Average Volume
2.30 million shares
Today's Range
$141.75
$144.70
50-Day Range
$141.58
$158.63
52-Week Range
$127.59
$187.35
Dividend Yield
2.92%
Haleon stock logo

36. Haleon NYSE:HLN

$8.96 +0.01 (+0.06%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$8.96 0.00 (0.00%)
As of 06/18/2026 06:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More about Haleon

Pros of Haleon

  • The current stock price is around $9.08, which may present a buying opportunity for investors looking for value in the consumer healthcare sector.
  • Haleon plc has a diverse product portfolio, including well-known brands in oral health, vitamins, and over-the-counter medications, which can help stabilize revenue streams.
  • The company has a long history, founded in 1715, which may instill confidence in its operational stability and experience in the market.

Cons of Haleon

  • There has been a notable decrease in shares shorted over the past month, indicating some investor skepticism about the stock's future performance.
  • The company has reported zero institutional ownership, which may suggest a lack of confidence from larger investors in its growth potential.
  • Haleon plc's short percentage of float is relatively low, which could indicate limited interest from investors looking to bet against the stock.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$39.64 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
N/A
Volume
18.83 million shares
Average Volume
9.03 million shares
Today's Range
$8.77
$8.98
50-Day Range
$8.71
$10.00
52-Week Range
$8.65
$11.28
Dividend Yield
2.82%
Alnylam Pharmaceuticals stock logo

37. Alnylam Pharmaceuticals NASDAQ:ALNY

$278.09 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$276.38 -1.71 (-0.62%)
As of 06/18/2026 07:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More about Alnylam Pharmaceuticals

Pros of Alnylam Pharmaceuticals

  • The company recently reported a significant increase in quarterly revenue, showcasing a year-over-year growth of nearly 100%, which indicates strong demand for its products.
  • Alnylam Pharmaceuticals, Inc. achieved a remarkable earnings per share (EPS) of $1.99 in its latest quarter, surpassing analysts' expectations, which reflects effective management and operational efficiency.
  • The current stock price is around $377, which is considered attractive given the company's strong financial performance and growth potential.

Cons of Alnylam Pharmaceuticals

  • The stock has a high price-to-earnings (P/E) ratio of approximately 79.83, which may suggest that the stock is overvalued compared to its earnings, potentially leading to a price correction.
  • Despite strong revenue growth, the company has a history of negative earnings per share in previous quarters, which could raise concerns about its long-term profitability.
  • Alnylam Pharmaceuticals, Inc. operates in a highly competitive biopharmaceutical market, which may pose risks to its market share and future growth prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$37.13 billion
P/E Ratio
75.98
Consensus Rating
Moderate Buy
Consensus Price Target
$463.13 (+66.5% Upside)
Volume
2.20 million shares
Average Volume
1.10 million shares
Today's Range
$273.11
$282.98
50-Day Range
$278.09
$339.41
52-Week Range
$273.11
$495.55
Dividend Yield
N/A
Teva Pharmaceutical Industries stock logo

38. Teva Pharmaceutical Industries NYSE:TEVA

$31.50 +0.02 (+0.06%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$31.40 -0.10 (-0.31%)
As of 06/18/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Market Capitalization
$36.20 billion
P/E Ratio
23.68
Consensus Rating
Moderate Buy
Consensus Price Target
$41.78 (+32.6% Upside)
Volume
12.24 million shares
Average Volume
5.99 million shares
Today's Range
$30.80
$32.38
50-Day Range
$30.66
$36.36
52-Week Range
$14.99
$37.35
Dividend Yield
N/A
Agilent Technologies stock logo

39. Agilent Technologies NYSE:A

$127.49 +0.43 (+0.34%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$124.70 -2.79 (-2.19%)
As of 06/18/2026 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • Agilent Technologies, Inc. has set its FY 2026 guidance for earnings per share (EPS) between 6.000 and 6.100, indicating strong expected profitability and growth potential.
  • The company recently announced a quarterly dividend of $0.255 per share, which translates to an annualized dividend yield of approximately 0.7%. This can provide a steady income stream for investors.
  • Agilent Technologies, Inc. has a low dividend payout ratio of 20.48%, suggesting that it retains a significant portion of its earnings for reinvestment, which can fuel future growth.

Cons of Agilent Technologies

  • Despite the positive outlook, the stock market can be volatile, and Agilent Technologies, Inc. may face fluctuations in stock price that could impact short-term investors.
  • The company operates in a highly competitive industry, which may pressure profit margins and affect its ability to maintain growth rates.
  • Economic uncertainties and changes in regulatory environments can pose risks to Agilent Technologies, Inc.'s operations and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$35.89 billion
P/E Ratio
25.60
Consensus Rating
Moderate Buy
Consensus Price Target
$160.93 (+26.2% Upside)
Volume
4.33 million shares
Average Volume
2.56 million shares
Today's Range
$125.17
$127.56
50-Day Range
$110.43
$138.23
52-Week Range
$108.35
$160.27
Dividend Yield
0.80%
Waters stock logo

40. Waters NYSE:WAT

$356.26 +0.82 (+0.23%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$355.45 -0.81 (-0.23%)
As of 06/18/2026 05:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Further, the company provides thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.

Market Capitalization
$34.90 billion
P/E Ratio
45.27
Consensus Rating
Moderate Buy
Consensus Price Target
$394.56 (+10.7% Upside)
Volume
1.44 million shares
Average Volume
928,305 shares
Today's Range
$353.56
$360.65
50-Day Range
$291.73
$384.12
52-Week Range
$275.05
$414.15
Dividend Yield
N/A
Revolution Medicines stock logo

41. Revolution Medicines NASDAQ:RVMD

$162.99 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$163.50 +0.51 (+0.31%)
As of 06/18/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Market Capitalization
$34.65 billion
P/E Ratio
N/A
Consensus Rating
Buy
Consensus Price Target
$123.72 (-24.1% Downside)
Volume
4.70 million shares
Average Volume
2.80 million shares
Today's Range
$158.40
$164.78
50-Day Range
$96.22
$163.68
52-Week Range
$34.00
$166.50
Dividend Yield
N/A
Natera stock logo

42. Natera NASDAQ:NTRA

$231.41 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$233.35 +1.94 (+0.84%)
As of 06/18/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Market Capitalization
$33.14 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
$256.53 (+10.9% Upside)
Volume
2.63 million shares
Average Volume
1.25 million shares
Today's Range
$227.93
$237.15
50-Day Range
$186.36
$231.41
52-Week Range
$131.81
$256.36
Dividend Yield
N/A
Zoetis stock logo

43. Zoetis NYSE:ZTS

$78.69 -0.02 (-0.03%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$78.70 +0.01 (+0.01%)
As of 06/18/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. More about Zoetis

Pros of Zoetis

  • The company has shown a steady revenue growth of approximately 2.9% year-over-year, indicating resilience and potential for continued expansion in the animal health market.
  • Zoetis Inc. has set its fiscal year 2026 earnings per share (EPS) guidance between 6.850 and 7.000, suggesting a positive outlook for profitability in the coming years.
  • The current stock price is around $75, which may present a buying opportunity for investors looking for value in the animal health sector.

Cons of Zoetis

  • Recent legal challenges, including securities-fraud litigation, may create uncertainty and negatively impact investor sentiment.
  • Concerns over weakening veterinarian adoption and prescription trends have been raised, which could affect future sales and growth potential.
  • Despite a positive revenue growth, the company recently reported earnings that fell short of consensus estimates, which may raise red flags for potential investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.00 billion
P/E Ratio
13.05
Consensus Rating
Hold
Consensus Price Target
$133.92 (+70.2% Upside)
Volume
17.09 million shares
Average Volume
6.61 million shares
Today's Range
$77.31
$79.06
50-Day Range
$74.11
$122.69
52-Week Range
$72.38
$161.77
Dividend Yield
2.69%
Alcon stock logo

44. Alcon NYSE:ALC

$64.77 +0.09 (+0.14%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$64.69 -0.08 (-0.12%)
As of 06/18/2026 04:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alcon Inc researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. More about Alcon

Pros of Alcon

  • The current stock price is around $87.48, which reflects a stable valuation in the market.
  • Alcon Inc. has shown a month-to-month increase in shares shorted, indicating growing interest and potential confidence from investors.
  • With an institutional ownership percentage of approximately 72.64%, a significant portion of shares is held by institutional investors, suggesting strong backing and confidence in the company's future.

Cons of Alcon

  • The fifty-two week performance shows a decline of about 7.53%, which may raise concerns about the company's growth trajectory.
  • There has been a recent increase in the short percentage of float, currently at 1.44%, which could indicate that some investors are betting against the stock.
  • Although the average daily volume is decent, it has not significantly increased, which may suggest a lack of strong momentum in the stock price.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$31.99 billion
P/E Ratio
39.02
Consensus Rating
Moderate Buy
Consensus Price Target
$85.12 (+31.4% Upside)
Volume
2.00 million shares
Average Volume
1.80 million shares
Today's Range
$63.84
$64.92
50-Day Range
$61.98
$81.35
52-Week Range
$61.83
$92.55
Dividend Yield
N/A
Royalty Pharma stock logo

45. Royalty Pharma NASDAQ:RPRX

$52.96 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$53.88 +0.92 (+1.74%)
As of 06/18/2026 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. More about Royalty Pharma

Pros of Royalty Pharma

  • The current stock price is around $51, which is near its 50-day moving average, indicating potential stability in the short term.
  • Royalty Pharma plc has demonstrated strong financial performance, with a recent earnings per share (EPS) of $1.30, surpassing analyst expectations, which reflects effective management and profitability.
  • The company boasts a solid return on equity of 29.25%, suggesting that it is efficient in generating profits from its equity investments.

Cons of Royalty Pharma

  • The company reported revenue of $630.58 million, which fell short of analyst expectations, indicating potential challenges in meeting growth targets.
  • Royalty Pharma plc has a relatively high price-to-earnings (P/E) ratio of 36.88, which may suggest that the stock is overvalued compared to its earnings, posing a risk for new investors.
  • The debt-to-equity ratio stands at 0.86, indicating that the company has a significant amount of debt relative to its equity, which could be a concern if market conditions change.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$30.50 billion
P/E Ratio
36.03
Consensus Rating
Buy
Consensus Price Target
$53.71 (+1.4% Upside)
Volume
8.61 million shares
Average Volume
4.12 million shares
Today's Range
$51.15
$54.38
50-Day Range
$47.91
$55.87
52-Week Range
$34.08
$56.50
Dividend Yield
1.77%
Centene stock logo

46. Centene NYSE:CNC

$61.06 +0.04 (+0.07%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$60.85 -0.21 (-0.34%)
As of 06/18/2026 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. More about Centene

Pros of Centene

  • The current stock price is approximately $32.68, which may present a buying opportunity for investors looking for value.
  • Centene Co. has shown a significant month-to-month increase in shares shorted, indicating growing interest and potential confidence from investors.
  • The company has a relatively low short percentage of float, suggesting that most investors are optimistic about its future performance.

Cons of Centene

  • The company has experienced a 52-week performance of 0%, indicating a lack of growth over the past year, which may concern potential investors.
  • There has been a notable increase in shares shorted, which could suggest that some investors are betting against the stock, reflecting negative sentiment.
  • With a float size of zero reported in one instance, this raises questions about the availability of shares for trading, potentially leading to volatility.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$30.13 billion
P/E Ratio
N/A
Consensus Rating
Hold
Consensus Price Target
$60.24 (-1.4% Downside)
Volume
11.82 million shares
Average Volume
5.08 million shares
Today's Range
$60.37
$61.98
50-Day Range
$37.25
$66.23
52-Week Range
$25.08
$66.55
Dividend Yield
N/A
BeOne Medicines stock logo

47. BeOne Medicines NASDAQ:ONC

$270.15 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$270.56 +0.41 (+0.15%)
As of 06/18/2026 06:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Market Capitalization
$29.64 billion
P/E Ratio
60.44
Consensus Rating
Moderate Buy
Consensus Price Target
$390.00 (+44.4% Upside)
Volume
367,884 shares
Average Volume
267,452 shares
Today's Range
$265.02
$274.55
50-Day Range
$260.27
$323.87
52-Week Range
$239.25
$385.22
Dividend Yield
N/A
Biogen stock logo

48. Biogen NASDAQ:BIIB

$196.58 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$196.00 -0.58 (-0.29%)
As of 06/18/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. More about Biogen

Pros of Biogen

  • Biogen Inc. recently reported earnings per share that significantly exceeded analysts' expectations, indicating strong financial performance and potential for future growth.
  • The company has set ambitious guidance for fiscal year 2026, projecting earnings per share between 14.250 and 15.250, which suggests confidence in its upcoming product pipeline and market strategies.
  • With a current stock price around $215, Biogen Inc. is positioned within a competitive range that may attract investors looking for growth in the biotechnology sector.

Cons of Biogen

  • Despite recent earnings growth, the company's revenue growth was only modest, which may raise concerns about its ability to sustain momentum in a competitive market.
  • There is a mixed outlook from analysts, with some maintaining a "Hold" rating, suggesting uncertainty about the stock's future performance.
  • Biogen Inc. operates in a highly regulated industry, and any changes in healthcare policies or regulations could adversely affect its business operations and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$29.02 billion
P/E Ratio
21.09
Consensus Rating
Moderate Buy
Consensus Price Target
$217.37 (+10.6% Upside)
Volume
1.72 million shares
Average Volume
918,468 shares
Today's Range
$193.20
$200.99
50-Day Range
$172.97
$204.53
52-Week Range
$121.05
$205.97
Dividend Yield
N/A
GE HealthCare Technologies stock logo

49. GE HealthCare Technologies NASDAQ:GEHC

$61.59 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$61.13 -0.46 (-0.75%)
As of 06/18/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. More about GE HealthCare Technologies

Pros of GE HealthCare Technologies

  • The current stock price is around $66, which is significantly lower than its twelve-month high, indicating potential for growth.
  • GE HealthCare Technologies Inc. reported a revenue increase of 7.4% year-over-year, showcasing strong business performance and demand for its products.
  • The company has a solid return on equity of over 20%, suggesting effective management and profitability relative to shareholder equity.

Cons of GE HealthCare Technologies

  • The company recently missed earnings expectations, reporting $0.99 per share against a consensus estimate of $1.07, which may raise concerns about its short-term performance.
  • GE HealthCare Technologies Inc. has a debt-to-equity ratio of 0.95, indicating a relatively high level of debt compared to equity, which could pose risks in a rising interest rate environment.
  • The stock has a beta of 0.74, suggesting lower volatility compared to the market, which may limit potential gains during bullish market conditions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$28.02 billion
P/E Ratio
14.73
Consensus Rating
Moderate Buy
Consensus Price Target
$80.21 (+30.2% Upside)
Volume
8.34 million shares
Average Volume
4.23 million shares
Today's Range
$59.97
$62.04
50-Day Range
$59.49
$74.67
52-Week Range
$58.75
$89.77
Dividend Yield
0.23%
IQVIA stock logo

50. IQVIA NYSE:IQV

$168.14 +0.37 (+0.22%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$169.65 +1.51 (+0.90%)
As of 06/18/2026 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More about IQVIA

Pros of IQVIA

  • The current stock price is around $168, which may be considered attractive compared to its 12-month high of $247.04, suggesting potential for growth.
  • Recent quarterly earnings showed a strong performance with earnings per share (EPS) of $2.90, exceeding analysts' expectations, indicating robust financial health.
  • The company reported a revenue increase of 8.4% year-over-year, reflecting strong demand for its services in the life sciences sector.

Cons of IQVIA

  • The company has a relatively high debt-to-equity ratio of 2.20, which may indicate higher financial risk and reliance on debt financing.
  • Recent analyst reports have shown mixed sentiments, with some firms lowering their price targets, which could reflect concerns about future growth potential.
  • The current ratio and quick ratio are both at 0.75, suggesting potential liquidity issues, as these ratios indicate the company may not have enough short-term assets to cover its short-term liabilities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$28.00 billion
P/E Ratio
20.84
Consensus Rating
Moderate Buy
Consensus Price Target
$222.56 (+32.4% Upside)
Volume
3.67 million shares
Average Volume
1.54 million shares
Today's Range
$162.22
$171.00
50-Day Range
$156.42
$187.14
52-Week Range
$153.01
$247.04
Dividend Yield
N/A